Deans' stroke musings: Stem cell company Athersys gets grant to study traumatic brain injury

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, February 2, 2012

Stem cell company Athersys gets grant to study traumatic brain injury

http://www.medcitynews.com/2012/02/stem-cell-company-athersys-gets-grant-to-study-traumatic-brain-injury/?utm_source=rss&utm_medium=rss&utm_campaign=stem-cell-company-athersys-gets-grant-to-study-traumatic-brain-injury

Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury.

A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement from Cleveland-based Athersys.

The grant will fund research that will include preclinical safety and efficacy studies required to support an Investigational New Drug (IND) application, as well as the clinical investigation of MultiStem to treat TBI.

Athersys’ MultiStem technology is an off-the-shelf stem cell treatment derived from the bone marrow of adults or other nonembryonic sources. The technology has shown promise in reducing inflammation, protecting damaged tissue and forming new blood vessels.

Athersys is investigating MultiStem for several applications, including heart attack, inflammatory bowel disease, stroke and blood diseases.

Another grant for $1.2 million comes from the government of Belgium and was awarded to Athersys’ subsidiary in Belgium, called ReGenesys BVBA. Athersys will use the funding to further develop cell therapy formulations and manufacturing capabilities, according to the statement.

Athersys apparently received another grant for $500,000, which would be necessary to arrive at the $3.6 million figure. But the company didn’t provide any details on the grant and a company official didn’t immediately respond to an email.

Late last year, Athersys closed a stock purchase deal with Aspire Capital Fund that could be worth up to $20 million.